US$ 23.75
pfizer glp 1 oral Danuglipron Pfizer axes oral GLP-1 asset,
Description
Hsu, J., et al

& Hua, X
There are notable differences between the two

One potential mechanism could be increased prevalence of NAION risk factors in patients starting GLP-1RA or that sudden and rapid decline in blood glucose could increase the risk of diabetic papillopathy or worsened DR

The side effect profiles differ

Whether you are seriously considering MEDVi or just beginning to explore your options, this review will give you the information you need to decide with confidence
